News-Medical.Net on MSN
Medicaid expansion boosts PrEP access for people at risk of HIV diagnosis
Medicaid expansion under the Affordable Care Act (ACA) significantly increased the number of people at risk of HIV diagnosis ...
Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...
Rutgers Health researchers found that prescription rates for preexposure prophylaxis rose overall, but racial disparities ...
Zacks Investment Research on MSN
GILD's Investigational Regimen for HIV Treatment Meets Primary Goal
Gilead Sciences, Inc. GILD announced that its investigational single-tablet regimen (STR) of bictegravir and lenacapavir for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback